As therapeutic potential of HDAC6 inhibition has been evaluated in cardiovascular, neurodegenerative diseases and cancers, recent studies have assessed the role of HDAC6 inhibition in endothelial dysfunction-derived ALI (Kovacs et al., 2018; Zhang et al., 2021). Here, HDAC6 is linked to endothelial dysfunction.